8
Oct
2024

Eurofins Advinus & Eurofins BPT

Exhibitor at CPHI Milan 2024 stand 5B109, Contract Manufacturing and Services
About Us

Eurofins Advinus is a premier contract research organization serving diverse industries to help advance their R&D programs within defined timelines & highest level of quality. We offer complete suite of drug discovery, preclinical & early clinical development services. Our CMC services help with drug substance development & manufacturing. We are known for our reliable services in Route Scouting, Process Development, Analytical Method Development & Manufacturing of drug substance for preclinical to Phase III & commercial use. Contact Us - [email protected]

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Contract Service
Primary activities
Analytical Services
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Intermediates Manufacturer
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 5B109, Contract Manufacturing and Services

Eurofins Advinus Limited Resources (1)

  • Eurofins Advinus CDMO Services

    Video Eurofins Advinus CDMO Services

    Explore our comprehensive solutions that seamlessly integrate process chemistry expertise with cutting-edge analytical solutions to accelerate your R&D. As a leading Contract Development & Manufacturing Organization (CDMO), we specialize in providing unparalleled services for the development of NCEs, APIs, Intermediates and drug products. At Eurofins Advinus you will find the best blend of quality, reliability, and competence in chemistry. Accelerate your drug discovery & development projects as we support you with quick synthesis of material to meet your preclinical requirements to phase III and commercial manufacturing.
    2024-02-19